Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

BACKGROUND: While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood. We exami...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Kiniwa, Yukiko, Nakamura, Kenta, Mikoshiba, Asuka, Ashida, Atsuko, Akiyama, Yasuyuki, Morimoto, Atsushi, Okuyama, Ryuhei
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7968258/
https://ncbi.nlm.nih.gov/pubmed/33731038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08016-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars